Frontiers in Biomedical Sciences
Articles Information
Frontiers in Biomedical Sciences, Vol.1, No.1, Sep. 2016, Pub. Date: Aug. 19, 2016
Conformational Analysis and Excited State Properties of a Competitive Inhibitor of Deoxyguanosine Triphosphate, 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one (Ganciclovir)
Pages: 26-30 Views: 2703 Downloads: 351
Authors
[01] F. J. Amaku, Department of Chemistry, Michael Okpara University of Agriculture, Umudike, Nigeria.
[02] I. E. Otuokere, Department of Chemistry, Michael Okpara University of Agriculture, Umudike, Nigeria.
Abstract
Ganciclovir, (2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one) is an acyclic analog of the nucleoside guanosine. Ganciclovir is widely used for the treatment of cytomegalovirus (CMV) infections among patients with impaired cell-mediated immunity, particularly persons with poorly controlled and advanced HIV/AIDS and recipients of solid organ and bone marrow transplantation, who are at high risk for invasive CMV disease. Computer aided geometry optimization (active conformation) and excited state properties of Ganciclovir was performed by ArgusLab 4.0.1 software. Result showed that the best conformation of Ganciclovir was found to be -126.872353 au(-79613.675800 kcal/mol) which is the minimum potential energy calculated by ArgusLab software using AMI/RHF method. At this point, Ganciclovir will be more active to interact with the receptors. Such types of interactions are significant for drug- receptor interactions.
Keywords
Ganciclovir, ArgusLab, Geometry Optimization, Receptor
References
[01] Crumpacker, C. S. (1996). Ganciclovir. N Engl J Med, 335: 721.
[02] Faulds, D. and Heel, R. C. (1990). Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990: 39: 597.
[03] Markham, A. and Faulds, D. (1994). Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994: 48: 455.
[04] Cohen, J. I., Davenport, D. S. and Stewart, J. A. (2002). Recommendations for prevention of and therapy forexposure to B virus (cercopithecine herpesvirus 1). Clin Infect Dis, 35: 1191.
[05] Mavros, M. N., Kapaskelis, A. and Falagas, M. E. (2010). Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol, 49: 151.
[06] Venturi, C., Bueno, J. and Gavalda, J.(2009).Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report .Transplant Proc, 41: 1038.
[07] Crowder, G. A. (1986). Conformational analysis of 3,3-dimethylhexane, Int. J. Rapid. Comm., 19(7): 783–789.
[08] Cramer, C. J. (2004). Molecular Mechanics. In: Essentials of Computational Chemistry. Theories and Models, 2nd ed., John Wiley and Sons Ltd., England, 36.
[09] Thompson, M. (2004). ArgusLab 4.0.1. Planaria software LLC, Seattle.
[10] Dunn, I. I. I. and Hopfinger, AJ. (1998). Drug Discovery, Kluwer Academic Publishers, 12, 167.
[11] Cruciani, G., Clementi, S. and Pastor, M. (1998). Perspectives in Drug Discovery and Design, 16: 71.
[12] Dewar, M. J. S., Zoobisch, E. G., Healy, E. F. and Stewart, J. J. P. (1985). AM1: A new general purpose quantum mechanical molecular model, J. Am. Chem. Soc.107, 3902–3910.
[13] Simons, J., Jorgensen, P., Taylor, H. and Ozment, J (1983) Walking on potential energy surfaces, J. Phys. Chem.87, 2745-2753.
[14] Csizmadia, I. G. and Enriz, R. D (2001). Peptide and protein folding, J. Mol. Struct.-Theochem., 543, 319–361.
[15] Martin, Y. C. (1998), Perspective in drug discovery and design, Springer Publisher, USA, 12, 3-23.
[16] http://www.thefreedictionary.com
[17] Pearson, R. G (1986). Absolute Electronegativity and Hardness Correlated with Molecular Orbital Theory. Proceedings of the National Academy of Sciences of the United States of America, 83: 8440-8441.
[18] Rappe, A. K., Casewit, C. J., Colwell, K. S., Goddard III, W. A. and Skiff, W. M. (1992)."UFF, a Full Periodic Table Force Field for Molecular Mechanics and Molecular Dynamics Simulations", J. Am. Chem. Soc., 114: 10024-10035.
[19] http://www.cmbi.ru.nl/molden/mapped.html
[20] Laxmi, K. (2014). Theoretical approach on structuralaspects of antiepileptic agent indoline-2,3-dione-3-oxime by arguslab 4 software. Journal of Applied Chemistry. 2(1): 92-101.
[21] Amaku, F. J, Otuokere, I. E and Igwe, K. K (2016). Computational study on the geometry optimization and excited – state properties of oxybuprocaine by ArgusLab 4.0.1 software, Journal of International Research in Medical and Pharmaceutical Sciences, 8(1): 33-39.
[22] Amaku, F. J. and Otuokere, I. E. (2016)Theoretical Approach on Structural Aspects of a Potent, Selective, Orally Bioavailable Hedgehog Antagonist, 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide,Indian Journal of Advances in Chemical Science 4(1): 31-35
[23] Otuokere, I. E. and Alisa, C. O. (2014) Molecular mechanics steric energy evaluation of reversible acetyl cholinesterase inhibitor, donepezil, (RS)-2-([1-benzyl-4-piperidyl] methyl)-5,6-dimethoxy-2,3-dihydroinden-1-one, Indian Journal of Advances in Chemical Science, 3: 87-95.
[24] Amaku, F. J and Otuokere, I. E. (2015). Conformational Analysis of a Potent Anticancer Drug 3-(4-amino-1-oxo-1,3-dihydro-2h-isoindol-2-yl) Piperidine-2,6-Dione (Lenalidomide), International Journal of Materials Chemistry and Physic,1(3): 406–410.
600 ATLANTIC AVE, BOSTON,
MA 02210, USA
+001-6179630233
AIS is an academia-oriented and non-commercial institute aiming at providing users with a way to quickly and easily get the academic and scientific information.
Copyright © 2014 - American Institute of Science except certain content provided by third parties.